{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(2)"],"submitter":["Teran E"],"pubmed_abstract":["<h4>Background</h4>Claudin 18.2 (CLDN18.2) is highly expressed in up to 40% of gastroesophageal adenocarcinomas (GEA) and represents an emerging therapeutic target for these tumors. However, its distribution across molecular subtypes and its prognostic and predictive roles remain insufficiently studied.<h4>Methods</h4>This ambispective, multicenter study included 563 patients with GEA diagnosed between 2019 and 2025 across 17 European institutions. Tumor samples were analyzed for CLDN18.2, human epidermal growth factor receptor 2 (HER2), mismatch repair, Epstein-Barr virus (EBV), and programmed death-ligand 1 [PD-L1; combined positive score (CPS)] using immunohistochemistry and/or in situ hybridization. Molecular alterations were characterized using next-generation sequencing. Associations"],"journal":["ESMO open"],"pagination":["106053"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12865641"],"repository":["biostudies-literature"],"pubmed_title":["Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort."],"pmcid":["PMC12865641"],"pubmed_authors":["Elez E","Alsina M","Teran E","Agra C","Foti S","Blanco C","Reboredo M","Vivancos A","Macarulla T","Zucchiatti A","Lopez A","Acosta D","Garcia-Paredes B","Tian TV","Sauri T","Fornaro L","Tabernero J","Landolfi S","Macias I","Pazo R","Ales I","Genovesi V","Martinez J","Visa L","Herranz JM","Vidal-Tocino R","Hierro C","Ribera P","Calvo A","Buges C","Martinez E","Carita L"],"additional_accession":[]},"is_claimable":false,"name":"Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort.","description":"<h4>Background</h4>Claudin 18.2 (CLDN18.2) is highly expressed in up to 40% of gastroesophageal adenocarcinomas (GEA) and represents an emerging therapeutic target for these tumors. However, its distribution across molecular subtypes and its prognostic and predictive roles remain insufficiently studied.<h4>Methods</h4>This ambispective, multicenter study included 563 patients with GEA diagnosed between 2019 and 2025 across 17 European institutions. Tumor samples were analyzed for CLDN18.2, human epidermal growth factor receptor 2 (HER2), mismatch repair, Epstein-Barr virus (EBV), and programmed death-ligand 1 [PD-L1; combined positive score (CPS)] using immunohistochemistry and/or in situ hybridization. Molecular alterations were characterized using next-generation sequencing. Associations","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-15T06:38:16.625Z","creation":"2026-07-02T03:08:43.469Z"},"accession":"S-EPMC12865641","cross_references":{"pubmed":["41604819"],"doi":["10.1016/j.esmoop.2025.106053"]}}